Arthur He
Stock Analyst at HC Wainwright & Co.
(3.11)
# 1,219
Out of 4,502 analysts
44
Total ratings
40.74%
Success rate
4.46%
Average return
Main Sectors:
Top Industries:
8 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ADAG Adagene | Reiterates: Buy | $5 | $2.74 | +82.82% | 7 | Jul 22, 2024 | |
| LVTX LAVA Therapeutics | Reiterates: Buy | $6 | $1.98 | +203.03% | 7 | Jun 28, 2024 | |
| HOOK HOOKIPA Pharma | Maintains: Buy | $50 → $60 | $6.02 | +896.68% | 6 | Jun 5, 2024 | |
| CALT Calliditas Therapeutics AB (publ) | Downgrades: Neutral | $39 | $38.26 | +1.95% | 4 | May 28, 2024 | |
| PSTX Poseida Therapeutics | Reiterates: Buy | $20 | $3.34 | +498.80% | 10 | May 22, 2024 | |
| PRME Prime Medicine | Initiates: Buy | $10 | $5.49 | +82.15% | 1 | May 20, 2024 | |
| SLDB Solid Biosciences | Reiterates: Buy | $16 | $8.84 | +81.00% | 3 | May 20, 2024 | |
| BCAB BioAtla | Reiterates: Buy | $7 | $1.71 | +309.36% | 6 | May 15, 2024 |
Adagene
Jul 22, 2024
Reiterates: Buy
Price Target: $5
Current: $2.74
Upside: +82.82%
LAVA Therapeutics
Jun 28, 2024
Reiterates: Buy
Price Target: $6
Current: $1.98
Upside: +203.03%
HOOKIPA Pharma
Jun 5, 2024
Maintains: Buy
Price Target: $50 → $60
Current: $6.02
Upside: +896.68%
Calliditas Therapeutics AB (publ)
May 28, 2024
Downgrades: Neutral
Price Target: $39
Current: $38.26
Upside: +1.95%
Poseida Therapeutics
May 22, 2024
Reiterates: Buy
Price Target: $20
Current: $3.34
Upside: +498.80%
Prime Medicine
May 20, 2024
Initiates: Buy
Price Target: $10
Current: $5.49
Upside: +82.15%
Solid Biosciences
May 20, 2024
Reiterates: Buy
Price Target: $16
Current: $8.84
Upside: +81.00%
BioAtla
May 15, 2024
Reiterates: Buy
Price Target: $7
Current: $1.71
Upside: +309.36%